Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. LFTO
2. CMCSA
3. QNT
4. NVDA
5. VRDN
6. INIO
7. HONA
8. ABBV
9. HON
10. SPY

Go back to Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer

Jefferies Cuts Price Target on Immunomedics (IMMU) as Clivatuzumab Program is Discontinued

March 15, 2016 8:15 AM EDT

Jefferies maintained a Hold rating on Immunomedics (NASDAQ: IMMU), and cut the price target to $1.50 (from $2.00), after the company decided to discontinue the ph 3 PANCRIT-1 trial testing clivatuzumab. The decision comes as a result of interim futility analysis by the independent Data and Safety... More